We previously demonstrated that a novel fusion protein MULT1E/FasTI expressed by TC-1 tumor cells inhibited tumor growth by simultaneously activating NKG2D expressing cells, such as NK cells, through the MULT1E portion and sending a death signal into cells through the Fas portion (Kotturi et al., Gene Therapy, 2008). In this study, an adenoviral gene delivery system was used to deliver this fusion protein. Our data indicate that adenoviral vector can efficiently deliver the MULT1E/FasTI fusion protein into TC-1 cells both in vitro and in vivo as assayed by RT-PCR, FACS analysis, caspase-3 activity and decreased in vivo tumor growth. This study further confirms that MULTE/FasTI represents a powerful bi-functional, therapeutic protein for the treatment of cancers.
Introduction
NK cells and/or other killer cells recognize and destroy virally infected cells and tumor cells through their surface receptors. [1] [2] [3] NKG2D is a stimulatory receptor expressed by NK cells, subsets of NKT cells and subsets of gamma delta T cells. 4, 5 Mouse NKG2D is also expressed by virtually all CD8 þ T cells and macrophages after stimulation. 6, 7 Mouse NKG2D ligands include retinoic acid early transcript 1 (Rae1), histocompatibility 60 (H60), 8 and mouse UL16-binding protein-like transcript 1 (MULT1). 9, 10 Fas (CD95) is a transmembrane cell surface death receptor that belongs to the tumor necrosis factor receptor superfamily. Binding of FasL (CD95L) to Fas receptor sends death signals to the cells and induces apoptosis. 11, 12 One of the strategies that tumor cells have developed to escape NKG2D-mediated cytolysis by NK cells or cells expressing NKG2D is down-regulating NKG2D ligands such as MICA, 13, 14 a process also called shedding. Tumor cells also escape Fas-mediated apoptosis by decreasing surface expression of Fas, 15, 16 secreting an antagonistic 'decoy' receptor, 17 expressing anti-apoptotic molecules such as BCL2 family members, 17, 18 down-regulating and mutating pro-apoptotic genes such as BAX, APAF1 or Fas. [19] [20] [21] [22] [23] In our earlier study 24 we combined the function of NKG2D-mediated cytolysis and Fas-mediated apoptosis into one functional fusion protein by using the extracellular domain of MULT1 and the transmembrane and intracellular domains of Fas in a mouse model. We created a bi-functional chimeric protein that not only sends apoptotic signal to the tumor cell expressing the fusion protein, but also activates NKG2D expressing cells such as NK cells. Our earlier in vitro and in vivo experimental data demonstrates that MULT1E/FasTI has clear antitumor properties. Here, we used a replication-defective adenovirus as a gene therapy vector to deliver this novel fusion protein into tumor cells. Our results indicate that MULT1E/FasTI delivered by the adenoviral vector is functional and effective in vitro and in vivo.
Materials and methods
Mice and cells C57BL/6J mice (female) at 6-8 weeks of age were purchased from Jackson Laboratories (Bar Harbor, ME) and housed in our pathogen-free animal facilities. The animal experiments were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH Publication Number 85-23) and the institutional guidelines. The mouse lung epithelial cancer cell line TC-1, obtained from the American Type Culture Collection (Manassas, VA), was cultured in RPMI 1640 medium with 2 mM L-glutamine, 1.5 g l À1 sodium bicarbonate, 4.5 g l À1 glucose, 0.1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 10% fetal bovine serum and 0.1 mg ml À1 gentamicin (GIBCO BRL Life Technologies, Gaithersburg, MD). 293A cells were maintained in DMEM (Medaitech, Herndon, VA) supplemented with 10% fetal bovine serum and 0.1 mg ml À1 gentamicin. All cell cultures were incubated at 37 1C under 5% CO 2 .
Construction of the adenoviral vectors and production of viral particles Ad-MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z adenovirus were generated using the ViraPower Adenoviral Expression System (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The full-length cDNAs of MULT1E/FasTI or cell membrane anchored MULT1E were obtained as reported earlier 24 and cloned into the pCR 8/GW/TOPO vector. The pCR 8/GW/ TOPO vector with MULT1E/FasTI or MULT1E inserts were used as entry clone vectors and transferred into the destination vector pAd/CMV/V5-DEST (Invitrogen) using the Gateway LR Clonase II enzyme mix according to the manufacturer's directions (Invitrogen) to generate pAd/CMV/MULT1E/FasTI/V5 and pAd/CMV/ MULT1E/V5. The vectors were linearized with PacI enzyme and transfected into 293A cell line using Lipofectamine 2000 reagent as per the manufacturer's directions. The 293A cells were maintained in DMEM medium until a cytophathic effect was apparent 5-7 days post-transfection. Cells were collected and lysed by subjecting them to four freeze/thaw cycles. The cell debris was pelleted at 3000 r.p.m. for 15 min and the supernatant was stored at À80 1C as crude viral lysate. Fifty microliters of crude viral lysate were added into each 293A cell culture dish and incubated for 2-3 days until an 80-100% cytophathic effect was observed. Two recombinant adenoviruses (Ad-MULT1E/FasTI and Ad-MULT1E) were harvested and purified using the Adeno-X virus Mini Purification Kit according to the manufacturer's directions (Clontech, Mountain View, CA) and stored at À80 1C. Ad-Lac-Z was purchased directly from the manufacturer (Clontech) and amplified as per the above method. Titers of Ad-MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z stocks were determined using an Adeno-X Rapid Titer Kit as per the manufacturer's directions (Clontech). 
RT-PCR

In vitro induction of apoptosis
To determine whether MULT1E/FasTI fusion protein delivered by adenoviral vector can send apoptotic signals into infected TC-1 cells in vitro, 5 Â 10 5 TC-1 cells were infected with 100 MOI of Ad-MULT1E/FasTI, Ad-MULT1E or Ad-Lac-Z for 24 h. The cells were then treated with 1 mg ml À1 of recombinant NKG2D/Fc (R&D Systems) for 16 h. Caspase-3 activity was measured using Caspase-3 Fluorometric Assay Kit (R&D Systems) according to the instructions provided by the manufacturer. To determine whether there is a dose effect of pfu on apoptosis, different MOIs of Ad-MULT1E/FasTI (500, 250, 100, 50, 25 and 0) were also tested. Briefly, 8 Â 10 5 cells from each sample were harvested, washed with PBS and lysed. The lysates were incubated with caspase-3 substrate for 1 h at 37 1C and the fluorescent signal was detected using a SpectraMax Gemini XS microplate reader (Molecular Devices, Sunnyvale, CA). The assay was performed in triplicates.
In vivo tumor study To study the therapeutic effect of Ad-MULT1E/FasTI in subcutaneous tumors, 2 Â 10 5 TC-1 cells were injected subcutaneously into the flank of 6-8-week-old C57BL/6J mice according to the animal care (NIH Publication Number 85-23) and institutional guidelines. When the tumors reached 40 mm 3 (about a week post-injection), Ad-MULT1E/FasTI, Ad-MULT1E, Ad-Lac-Z or HBSS were injected into individual tumors using a 0.5-ml U-100 insulin syringe with 281/2G needle. The virus particles (1 Â 10 9 pfu per tumor per dose) were given every other day for four doses. To monitor tumor progression in the mice, the longest (L) and shortest diameter (W) of the tumors were measured every 2 days with a linear caliper. The tumor volume was calculated as per the formula 1/2 LW 2 .
In vivo apoptosis detection
In vivo apoptosis in tumors treated with four injections of Ad-MULT1E/FasTI, Ad-MULT1E, Ad-Lac-Z or HBSS was detected using the FLIVO in vivo apoptosis detection reagent. One hundred microlitters of FLIVO in vivo apoptosis detection reagent was injected into the tail vein of mice with tumors 48 h after the last intratumoral injection. Thirty minutes later, the mice were killed and tumor tissue was exercised and frozen in liquid nitrogen. A measure of 7 mm frozen sections were prepared and the apoptosis in the tumor slides was visualized and photographed using an Olympus 1X70 fluorescent microscope (Olympus, Center Valley, PA). The data presented are the sum of apoptotic cells from 12 random fields of each section.
Statistical analysis
Results were expressed as means±s.d. The statistical significance between groups was assessed with GraphPad Prism 4 built-in softwares including student t-test, oneway analysis of variance (ANOVA) with Dunnett's post test and two-way analysis ANOVA with Bonferroni's post tests. Data are considered statistically significant if P-values were 0.05 or lower. 
Results
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MOI of Ad-MULT1E/FasTI and treated with NKG2D/ Fc, their caspase-3 activity was significantly higher (Po0.001) than the cells that were also infected by Ad-MULT1E/FasTI but not treated with NKG2D/Fc. Ad-MULT1E or Ad-Lac-Z infection only showed slightly increased caspase-3 activity (P40.05) compared with non-infected TC-1 cells (Figure 2a) . A similar pattern was obtained when the MOIs were increased to 250 (Figure 2b) . The caspase activity in Ad-MULT1E/FasTI infected and NKG2D treated TC-1 cells is adenoviral particle dose dependent: 500 MOI generated the highest caspase activity, whereas a 25 MOI did not show any increased caspase-3 activity compared with un-infected TC-1 cells (Figure 2c ).
Intratumor delivery of MULT1E/FasTI by adenoviral vectors
To observe the antitumor activity of MULT1E/FasTI delivered by adenoviral vectors, subcutaneous TC-1 tumors were grown in C57BL/6J mice. When the tumor reached about the size of 40 mm 3 , Ad-MULT1E/FasTI, Ad-MULT1E or Ad-Lac-Z at a dose of 1 Â 10 9 pfu per tumor in 0.05 ml HBSS was injected into the tumors. The injections were repeated every other day for four times. The size of the tumors was measured every 2 days. At day 22 after tumor cell injection, the mice were sacrificed and the tumors were collected and measured. Although tumors that received Ad-MULT1E or Ad-Lac-Z grew slightly slower than tumors received only HBSS, tumors that received Ad-MULT1E/FasTI showed the slowest growth rate. At days 20 and 22, the tumors were significantly smaller when compared with tumors received HBSS (Po0.05 and Po0.01, Figure 3a) . The end point tumor measurement confirmed the conclusion that Ad-MULT1E/FasTI treatment significantly delayed the tumor growth (Po0.05, Figure 3b ).
MULT1E/FasTI delivered by adenoviral vector induces apoptosis in tumor
To confirm that MULT1E/FasTI delivered by adenoviral vectors slows tumor growth by inducing tumor cells to undergo apoptosis, 2 days after the last adenoviral particle injection, some mice were i.v. injected with FLIVO in vivo apoptosis detection reagent. Thirty minutes later, the tumor tissues were collected and 7 mm frozen sections were produced. The slides were examined under fluorescent microscopy and the green fluorescent cells were counted. The number of apoptotic cells in tumors receiving Ad-MULT1E/FasTI is significantly higher than that of tumors receiving either Ad-MULT1E or Ad-Lac-Z. There are no significantly more apoptotic cells in tumors receiving Ad-MULT1E or Ad-Lac-Z when compared with tumors that received just HBSS (Figure 4 ).
Discussion
The findings of this study show the therapeutic effect of adenovirus-mediated gene therapy delivering the novel fusion protein MULT1E/FasTI. At present, adenoviruses are still an attractive vector to deliver desirable genes for the treatment of cancer because of its high infectivity in vivo, which allows for direct vector injection in the clinic, and avoids additional manipulations in vitro as required for other vector systems such as retroviruses. 25 The most encouraging preclinical finding from our study is that mice that received treatment with the Ad-MULTE/ FasTI fusion construct showed more apoptosis in vivo and formed smaller tumors.
We first examined the efficiency of adenoviral transduction and the effect of MOI on the expression level of the fusion protein in TC1 cells in vitro using RT-PCR and FACS staining. We observed that the expression of fusion protein MULT1E/FasTI delivered by adenoviral vectors is clearly viral particle dose dependent. Higher MOIs resulted in a marked increase in the expression level of the protein, where as lower MOIs caused reduced expression levels ( Figure 1) . Then, we showed that the MULT1E/ FasTI fusion protein delivered by the adenoviral vector It is interesting to note that TC-1 cells infected with Ad-MULT1E/FaxTI or Ad-MULT1E, but without NKG2D treatment, showed increased caspase-3 activity (Figure 2a ) and it increases with the rise of virus doses (Figure 2b ). There are at least two possibilities that can explain this phenomenon. The fusion protein may be activated nonspecifically by some factors presented in the culture system so that an apoptotic signal is sent to the cells; and/ or the virus infection may cause cells to undergo apoptosis, which is evidenced by the fact that Ad-Lac-Z-infected cells showed higher caspase activity than uninfected cells (Figure 2a and b) . In our future study, we will build a vector encoding only the Fas transmembrane and intracellular domains, which will partially answer this question. Furthermore, we will test this fusion protein in beige mice, which lack functional NK cells, or NKG2D knockout mice to determine whether the antitumor activity of the fusion is NKG2D dependent.
We also investigated the in vivo therapeutic effect of adenovirus-mediated MULT1E/FasTI gene therapy by intratumoral injections of viruses. The results show that the average tumors treated with Ad-MULT1E/FasTI were B50% smaller compared with HBSS-treated tumors. Tumor volumes of MULT1E/FasTI treatment group was significantly smaller on days 20 (Po0.05) and 22 (Po0.01) compared with other groups (Figure 3) . A repeated experiment with up to nine viral injections showed similar results (data not shown). This reduction in the size of the tumors can be attributed to more apoptosis in tumors treated with Ad-MULT1E/FasTI, which is confirmed by the FLIVO in vivo apoptosis detection reagent (Figure 4) . NKG2D recognition of multiple stress-inducible host proteins is of considerable research interest and the unique application of the NKG2D/stress proteins has the potential to be manipulated for therapeutic purposes. Tumor cells expressing NKG2D ligands have been shown to be susceptible to NK cell mediated lysis and induce a very potent antitumor immune response in vivo. 5, 9, 24 The failure of some tumor cells to die following drug treatment and their resultant resistance to these drugs is due to their failure to undergo apoptosis, as tumors cells have defects in triggering mechanisms of their own death by apoptosis. 26 The toxic side effects observed from the use of FasL or agonistic anti-Fas antibodies in vivo, resulting in a fatal hepatic damage with symptoms similar to fulminant hepatitis 27, 28 has encouraged a shift of focus to therapies that would enhance apoptosis by using Fas ligand independent activation of Fas. 26 Therefore, our fusion protein MULT1E/FasTI may be both novel and useful as it combines two different functionalities together into one functional protein. It activates NKG2D expressing immune cells through its MULT1E extracellular region and induces apoptosis through its FasTI region. However, the toxicity derived from the adenovirus vector itself still need to be addressed in the future studies since no adenoviral toxicity was monitored in this work.
In summary, our findings confirm that adenoviral mediated delivery and expression of MULT1E/FasTI fusion proteins represents a powerful new approach to destructively target tumors. Our approach therefore may provide a potential avenue for new cancer therapies and supports further investigation of MULT1E/FasTI therapeutic strategies for treating cancer. 
